JP2009544690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544690A5 JP2009544690A5 JP2009521410A JP2009521410A JP2009544690A5 JP 2009544690 A5 JP2009544690 A5 JP 2009544690A5 JP 2009521410 A JP2009521410 A JP 2009521410A JP 2009521410 A JP2009521410 A JP 2009521410A JP 2009544690 A5 JP2009544690 A5 JP 2009544690A5
- Authority
- JP
- Japan
- Prior art keywords
- ccl2
- dosage form
- unit dosage
- inflammation
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 230000007815 allergy Effects 0.000 claims 3
- 230000012292 cell migration Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83260006P | 2006-07-24 | 2006-07-24 | |
| PCT/IL2007/000806 WO2008012796A2 (en) | 2006-07-24 | 2007-06-28 | Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544690A JP2009544690A (ja) | 2009-12-17 |
| JP2009544690A5 true JP2009544690A5 (enExample) | 2010-08-12 |
Family
ID=38981868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521410A Pending JP2009544690A (ja) | 2006-07-24 | 2007-06-28 | Ｃｃｌ２を含む医薬組成物および炎症の処置のためのその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7919077B2 (enExample) |
| EP (1) | EP2056857B1 (enExample) |
| JP (1) | JP2009544690A (enExample) |
| AU (1) | AU2007278054B2 (enExample) |
| CA (1) | CA2658719A1 (enExample) |
| ES (1) | ES2434039T3 (enExample) |
| WO (1) | WO2008012796A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919077B2 (en) * | 2006-07-24 | 2011-04-05 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation |
| WO2010137020A1 (en) | 2009-05-28 | 2010-12-02 | Yeda Research And Development Co. Ltd. | Methods of treating inflammation |
| CN101829075B (zh) * | 2010-04-27 | 2011-07-20 | 中国人民解放军第三军医大学第一附属医院 | 苦柯胺a和苦柯胺b的用途 |
| WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| EP3288587A4 (en) * | 2015-04-29 | 2018-09-12 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
| WO2017062493A1 (en) * | 2015-10-05 | 2017-04-13 | Board Of Regents, The University Of Texas System | Micro-and nano-device for cartilage injury detection and treatment |
| KR102066149B1 (ko) * | 2018-08-17 | 2020-01-14 | 고려대학교 산학협력단 | Ccl2를 유효성분으로 포함하는 임신촉진용 조성물 |
| KR102154235B1 (ko) * | 2019-02-11 | 2020-09-09 | 고려대학교 산학협력단 | Ccl2를 유효성분으로 포함하는 산유량 증가용 조성물, 및 유방염 예방 또는 치료용 약학적 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05271093A (ja) * | 1992-03-30 | 1993-10-19 | Toray Ind Inc | 血管内皮細胞増殖剤 |
| AU4054197A (en) * | 1996-08-14 | 1998-03-06 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| GB0016138D0 (en) * | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE60027419D1 (de) * | 2000-07-06 | 2006-05-24 | Deutsches Krebsforsch | Regulatorische Sequenzen des humanen MCP-1 Gens |
| US7601692B2 (en) * | 2000-11-28 | 2009-10-13 | Compugen Ltd. | MCP-1 splice variants and methods of using same |
| TWI245761B (en) * | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
| AU2003265575B2 (en) * | 2002-08-19 | 2009-12-10 | Astrazeneca Ab | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
| JP4601936B2 (ja) * | 2002-10-29 | 2010-12-22 | 株式会社ミノファーゲン製薬 | Ｍｃｐ−１産生抑制のための薬学的組成物 |
| AR046594A1 (es) * | 2003-10-16 | 2005-12-14 | Applied Research Systems | Usos terapeuticos de variantes de quemoquina |
| CA2544924A1 (en) * | 2003-11-05 | 2005-05-19 | Centocor, Inc. | Methods and compositions for treating mcp-1 related pathologies |
| MX2008002101A (es) * | 2005-08-12 | 2008-04-19 | Schering Corp | Fusiones de la proteina-1 quimiotactica de monocito. |
| AU2007226155B2 (en) * | 2006-03-16 | 2014-04-03 | Protagonists Ltd. | Combination of cytokine and cytokine receptor for altering immune system functioning |
| US7919077B2 (en) * | 2006-07-24 | 2011-04-05 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation |
-
2007
- 2007-06-28 US US12/309,611 patent/US7919077B2/en not_active Expired - Fee Related
- 2007-06-28 JP JP2009521410A patent/JP2009544690A/ja active Pending
- 2007-06-28 WO PCT/IL2007/000806 patent/WO2008012796A2/en not_active Ceased
- 2007-06-28 ES ES07766836T patent/ES2434039T3/es active Active
- 2007-06-28 EP EP07766836.6A patent/EP2056857B1/en not_active Not-in-force
- 2007-06-28 AU AU2007278054A patent/AU2007278054B2/en not_active Ceased
- 2007-06-28 CA CA002658719A patent/CA2658719A1/en not_active Abandoned
-
2011
- 2011-03-17 US US13/049,976 patent/US20110165116A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544690A5 (enExample) | ||
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| HRP20120264T1 (hr) | Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe | |
| JP2016074740A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| NZ603579A (en) | Controlled release formulations | |
| JP2010533705A5 (enExample) | ||
| WO2008009476A3 (de) | Konzentrierte methotrexat-lösungen | |
| HRP20250568T1 (hr) | Režim doziranja agonista s1p receptora | |
| JP2011225596A5 (enExample) | ||
| JP2010511596A5 (enExample) | ||
| JP2007520506A5 (enExample) | ||
| RU2009142937A (ru) | Тапентадол для лечения в связи с остеоартрозом | |
| JP2010526837A5 (enExample) | ||
| HRP20140657T1 (hr) | Laminin-1 za primjenu radi pojaäśanja regeneracije mišiä†a nakon ozljede ili za bolje zacjeljivanje rana ako se daje sistemski | |
| RU2016134989A (ru) | Применение агонистов альфа-2в рецепторов для получения лекарственного средства и способы лечения (варианты) | |
| JP2016505023A5 (enExample) | ||
| WO2010092450A8 (en) | Stable pharmaceutical composition for atherosclerosis | |
| JP2013541583A5 (enExample) | ||
| JP2011190199A5 (enExample) | ||
| JP2020520963A5 (enExample) | ||
| JP2014508758A5 (enExample) | ||
| JP2010520184A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2013501049A5 (enExample) |